Submitted:
28 April 2025
Posted:
30 April 2025
You are already at the latest version
Abstract
Keywords:
Introduction
Methods
Study Design
Participant Recruitment and Eligibility Criteria
- Any Cancer stage
- Completion of cancer-related treatment within the past 12 months
- Age ≥ 21 years
- Consent to access health records
- Access to a smartphone or tablet
- Recent surgery within the past 4 weeks or scheduled surgery in the next 4 weeks
- Medically unfit for physical activity, as determined by a physician
- Eastern Cooperative Oncology Group (ECOG) performance status ≥ 3
Intervention and Control Conditions
- 30 min of structured physical activity (aerobic, strength, flexibility, and balance exercises)
- 7 min of guided meditation
Outcome Measures
- The primary outcome was total healthcare expenditures, encompassing both cancer-related and non-cancer-related costs. Secondary outcomes included:
- Quality of Life (QoL) measured using the Functional Assessment of Cancer Therapy-General (FACT-G) instrument
- Absenteeism, assessed through self-reported short-term and long-term leave status and average weekly work hours
- Presenteeism, evaluated based on self-reported changes in work motivation and performance
- Motivation and performance were quantified on a five-point Likert scale:
- Motivation: 1 (Very Demotivated) to 5 (Very Motivated)
- Performance: 1 (Unacceptable) to 5 (Excellent)
Data Collection and Statistical Analysis
Ethical Considerations
Results
Patient Demographics and Baseline Case Characteristics
Participant Engagement and Adherence to Intervention
Medical Expenditures

Quality of Life Outcomes
Overall FACT-G Score
Physical Well-Being (PWB)
Social Well-Being (SWB)
Emotional Well-Being (EWB)
Functional Well-Being (FWB)





Impact of the Intervention Across Quality-of-Life Metrics

Presenteeism at Work
Absenteeism from Work
Discussion
Conclusions
Appendix A
Randomisation
Randomization Approach
Block Sequence Design
RandID Structure
RandID Reservation Process
RandID Confirmation and Allocation
RandID Release Mechanism
Program Details
- Daily Live Physical Activity Coaching: Personalized exercise sessions across various modalities such as strength and conditioning, cardiovascular workouts, dance, and yoga, tailored precisely to participants’ data-driven physical capabilities and preferences.
- Daily Dietary Challenges: Coaches collaborate directly with participants on dietary challenges, based on AICR nutritional guidelines, fostering mutual accountability and adherence.
- Daily Somatic Practices: Structured meditation and breathwork sessions designed to heal deep-rooted trauma, removing barriers to sustained lifestyle change.

References
- 2024 Global Medical Trend Rates Report (Aon).
- Brown, Justin C.; Gilmore, L. Anne. Physical Activity Reduces the Risk of Recurrence and Mortality in Cancer Patients. Exercise and Sport Sciences Reviews 48(2):p 67-73, April 2020. |. [CrossRef]
- Christine M Friedenreich, Chelsea R Stone, Winson Y Cheung, Sandra C Hayes, Physical Activity and Mortality in Cancer Survivors: A Systematic Review and Meta-Analysis, JNCI Cancer Spectrum, Volume 4, Issue 1, February 2020, pkz080. [CrossRef]
- Mehta R, Sharma K, Potters L, et al. (May 09, 2019) Evidence for the Role of Mindfulness in Cancer: Benefits and Techniques. Cureus 11(5): e4629. [CrossRef]
- Christopher, M. Blanchard et al., Cancer Survivors’ Adherence to Lifestyle Behavior Recommendations and Associations With Health-Related Quality of Life: Results From the American Cancer Society’s SCS-II. JCO 26, 2198-2204(2008). [CrossRef]
- Overcoming Barriers to Maintaining Physical Activity during Cancer Care (MSKCC Research.
- Jianhui Zhao, Liying Xu, Jing Sun, Mingyang Song, Lijuan Wang, Shuai Yuan, Yingshuang Zhu, Zhengwei Wan, Susanna Larsson, Konstantinos Tsilidis, Malcolm Dunlop, Harry Campbell, Igor Rudan, Peige Song, Evropi Theodoratou, Kefeng Ding, Xue Li—Global trends in incidence, death, burden and risk factors of early-onset cancer from 1990 to 2019: BMJ Oncology 2023;2:e000049.
- Florence, C.S. , Bergen, G., Atherly, A., Burns, E., Stevens, J. and Drake, C. (2018), Medical Costs of Fatal and Nonfatal Falls in Older Adults. J Am Geriatr Soc, 66: 693-698. [CrossRef]
- Wonders, K., Harness, J. K., & Lerner, A. G. (2023). BPI23-010: The Benefits of a Clinically Based Individualized Exercise Oncology Program on Health Care Utilization in Patients With Malignancies. Journal of the National Comprehensive Cancer Network, 21(3.5), BPI23-010-BPI23-010. Retrieved Feb 27, 2025. [CrossRef]
- Grossman H, Burnell MJ, Bouchard DR. How One Community Exercise Program for People Living With Cancer Impacted Health Care Utilization. Oncology Issues. 2024;39(5):7-13. [CrossRef]
- Karen, Y. Wonders et al., Cost-Savings Analysis of an Individualized Exercise Oncology Program in Early-Stage Breast Cancer Survivors: A Randomized Clinical Control Trial. JCO Oncol Pract 18, e1170-e1180(2022). [CrossRef]
- J. F. Grutsch et al., Quality of life: An independent prognostic variable in a general population of cancer patients receiving chemotherapy. JCO 25, 19596-19596(2007). [CrossRef]
- Yost, K. J. , Thompson, C. A., Eton, D. T., Allmer, C., Ehlers, S. L., Habermann, T. M., … Cerhan, J. R. (2012). The Functional Assessment of Cancer Therapy—General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma. Leukemia & Lymphoma, 54(2), 290–297. [CrossRef]
- Therese, Djärv; et al., Prognostic Value of Changes in Health-Related Quality of Life Scores During Curative Treatment for Esophagogastric Cancer. JCO 28, 1666-1670(2010). [CrossRef]
- François, Meyer; et al., Health-Related Quality of Life As a Survival Predictor for Patients With Localized Head and Neck Cancer Treated With Radiation Therapy. JCO 27, 2970-2976(2009). [CrossRef]
- Braun, D.P. , Gupta, D., Grutsch, J.F. et al. Can changes in health related quality of life scores predict survival in stages III and IV colorectal cancer?. Health Qual Life Outcomes 9, 62 (2011). [CrossRef]
- Cowie J, Gurney M The Use of Facebook Advertising to Recruit Healthy Elderly People for a Clinical Trial: Baseline Metrics JMIR Res Protoc 2018;7(1):e20 URL: https://www.researchprotocols.org/2018/1/e2. [CrossRef]

| Intervention Group | Control Group | Total | ||
| Demographic | Total Participants | 84 | 74 | 158 |
| Median Age | 56 | 53 | 54 | |
| Intervention Group | Control Group | Total | ||
| Age Group | Below 45 | 10.6% | 18.9% | 14.5% |
| Between 45-54 | 29.4% | 41.9% | 35.2% | |
| 55 above | 60.0% | 39.2% | 50.3% | |
| Intervention Group | Control Group | Total | ||
| Cancer Type | Breast | 61.2% | 64.9% | 62.9% |
| Colorectal | 9.4% | 12.2% | 10.7% | |
| Lung | 3.5% | 2.7% | 3.1% | |
| Prostate | 3.5% | 4.1% | 3.8% | |
| Other | 22.4% | 16.2% | 19.5% | |
| Intervention Group | Control Group | Total | ||
| Cancer Stage | CIS* | 3.5% | 5.4% | 4.4% |
| I | 34.1% | 14.9% | 25.2% | |
| II | 14.1% | 24.3% | 18.9% | |
| III | 10.6% | 14.9% | 12.6% | |
| IV | 32.9% | 35.1% | 34.0% | |
| Unknown | 4.7% | 5.4% | 5.0% | |
| Intervention Group | Control Group | Total | ||
| Race and Ethnicity | White | 62.4% | 66.2% | 64.2% |
| Black | 15.3% | 10.8% | 13.2% | |
| Hispanic | 4.7% | 6.8% | 5.7% | |
| Other Minorities—Asian, Indian Origin and Others | 11.8% | 5.4% | 8.8% | |
| Unknown | 5.9% | 10.8% | 8.2% | |
| Parameter | Time Period |
No. of Patients | Intervention Group, MEAN (SD) |
Control Group, MEAN (SD) |
Difference—in—Difference, MEAN (SD) |
P Value |
|---|---|---|---|---|---|---|
| Medical Expenses | Baseline | 53 | $23,698.52 (28,960.9) | $30,049.71 (33485.76) | . | |
| Medical Expenses | Post Intervention | 53 | $14,942.18 (16,322.8) | $36,248.91 (41,469.15) | -$14,955.54 (6,107.06) | 0.0089 |
| Parameter | Time Period |
No. of Patients | Intervention Group, MEAN (SD) |
Control Group, MEAN (SD) |
Difference—in—Difference, MEAN (SD) |
P Value |
|---|---|---|---|---|---|---|
| Quality of Life (FACT-G) | Baseline | 158 | 70.48 (16.03) | 65.78 (16.09) | N/A | . |
| Quality of Life (FACT-G) | 3-Month | 81 | 78.03 (14.3) | 63.91 (19.58) | 10.84 (13.32) | 0.0002 |
| Parameter | Time Period |
No. of Patients | Intervention Group, MEAN (SD) |
Control Group, MEAN (SD) |
Difference—in—Difference, MEAN (SD) |
P Value |
|---|---|---|---|---|---|---|
| Motivation | Baseline | 158 | 2.29 (1.13) | 2.3 (1.08) | N/A | . |
| Motivation | 3-Month | 81 | 2.76 (0.79) | 2.26 (1.2) | 0.48 (1.15) | 0.0332 |
| Performance | Baseline | 158 | 2.2 (1.05) | 2.19 (0.96) | N/A | . |
| Performance | 3-Month | 81 | 2.53 (1.01) | 1.98 (1.22) | 0.48 (0.95) | 0.0130 |
| Parameter | Time Period |
No. of Patients | Intervention Group, MEAN (SD) |
Control Group, MEAN (SD) |
Difference—in—Difference, MEAN (SD) |
P Value |
|---|---|---|---|---|---|---|
| Working Hours | Baseline | 87 | 29.76 (14.79) | 24.51 (13.98) | N/A | . |
| Working Hours | 3-Month | 43 | 32.29 (14.59) | 20.05 (18.09) | 4.78 (11.95) | 0.0999 |
| Parameter | Time Period |
No. of Patients | Intervention Group, MEAN (SD) |
Control Group, MEAN (SD) |
Difference—in—Difference, MEAN (SD) |
P Value |
|---|---|---|---|---|---|---|
| Long Term Leave | Baseline | 158 | 85.71% (35.2%) | 79.73% (40.48%) | N/A | . |
| Long Term Leave | 3-Month | 81 | 84.21% (36.95%) | 72.09% (45.39%) | 2.33% (25.1%) | 0.3392 |
| Short Term Leave | Baseline | 158 | 88.1% (32.58%) | 81.08% (39.43%) | N/A | . |
| Short Term Leave | 3-Month | 81 | 97.37% (16.22%) | 88.37% (32.44%) | -6.36% (36.13%) | 0.2156 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).